B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic-ecollection
Typ dokumentu časopisecké články
PubMed
36276116
PubMed Central
PMC9583921
DOI
10.3389/fonc.2022.992137
Knihovny.cz E-zdroje
- Klíčová slova
- SARS-CoV-2, chronic lymphocytic leukemia (CLL), immune system COVID19, infection risk, lymphoproliferative diseases (LPD), non-Hodgkin lymphoma (NHL), targeted drugs,
- Publikační typ
- časopisecké články MeSH
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Amsterdam UMC location VUmc Amsterdam Netherlands
Ankara University Ankara Turkey
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Azienda Ospedaliera San Gerardo Monza Monza Italy
Centre Hospitalier de Versailles Versailles France
Communicable Disease Center Hamad Medical Corporation Doha Qatar
COVID Hospital Batajnica Belgrade Serbia
Croatian Cooperative Group for Hematological Diseases Zagreb Croatia
Departament de Medicina Universitat Autònoma de Barcelona Bellaterra Spain
Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Hematology University Hospital Dubrava Zagreb Croatia
Department of Medicine Section of Hematology University of Verona Verona Italy
Department of Nephrology and Infectious Diseases AZ Sint Jan Brugge Oostende AV Brugge Belgium
Division of Hematology and Oncology Weill Cornell Medicine New York NY United States
Faculty of Medicine and Faculty of Health Studies University of Rijeka Rijeka Croatia
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany
Health Research Institute IIS FJD Fundacion Jimenez Diaz University Hospital Madrid Spain
Health Research Institute IIS FJD Fundación Jimenez Diaz University Hospital Madrid Spain
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
Hematology Deparment Hospital Universitario Infanta Leonor Madrid Spain>
Hematology Department Hospital Universitario 12 de Octubre Madrid Spain
Hematology Department Hospital Universitario de Salamanca Salamanca Spain
Hematology Unit ASST Spedali Civili Brescia Italy
Hematology Unit Center for Translational Medicine Azienda USL Toscana NordOvest Livorno Italy
Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Hematology Unit Università Cattolica del Sacro Cuore Rome Italy
Hospital Campus Barcelona Spain
Hospital Nuestra Señora de Sonsoles Ávila Spain
Hospital Universitario Puerta de Hierro Majadahonda Spain
IBSAL Centro de Investigación del Cáncer IBMCC Salamanca Spain
Institute of Hematology and Blood Transfusion Prague Czechia
King's College Hospital London United Kingdom
King's College London London United Kingdom
La Paz University Hospital Madrid Spain
Laikon General Hospital Athens Greece
Medizinische Klinik 2 Klinikum rechts der Isar TU München Munich Germany
NIHR Oxford Biomedical Research Centre Churchill Hospital Oxford United Kingdom
Portuguese Institute of Oncology Lisbon Portugal
San Luigi Gonzaga Hospital Orbassano Orbassano Italy
Stem Cell Transplant Center AOU Citta' della Salute e della Scienza Turin Italy
U O Ematologia e Centro Trapianti Midollo Osseo Ospedale Maggiore Parma Italy
Università Milano Bicocca Milan Italy
University Clinic of Hematology Skopje North Macedonia
University Hospital Centre Rijeka Rijeka Croatia
University Hospital Olomouc Olomouc Czechia
University Hospital Ostrava Ostrava Czechia
Zobrazit více v PubMed
Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med (2020) 382:1708–20. doi: 10.1056/NEJMoa2002032 PubMed DOI PMC
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood (2020) 136:2881–92. doi: 10.1182/blood.2020008824 PubMed DOI PMC
Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH research collaborative data hub. Blood Adv (2020) 4:5966–75. doi: 10.1182/bloodadvances.2020003170 PubMed DOI PMC
Yigenoglu TN, Ata N, Altuntas F, Bascı S, Dal MS, Korkmaz S, et al. . The outcome of COVID-19 in patients with hematological malignancy. J Med Virol (2021) 93:1099–104. doi: 10.1002/jmv.26404 PubMed DOI PMC
Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, et al. . Infectious complications among individuals with clinical monoclonal b-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia (2013) 27:136–41. doi: 10.1038/leu.2012.187 PubMed DOI
Law N, Taplitz RA. How I manage infection risk and prevention in patients with lymphoid cancer. Blood (2022) 139:1517–28. doi: 10.1182/blood.2019003687 PubMed DOI
Ochoa-Grullón J, Peña Cortijo A, Guevara-Hoyer K, Jiménez García C, de la Fuente E, de la Peña AR, et al. . B-cell haematological malignancies and SARS-CoV-2 infection: Could immunological interventions influence the outcome? EJHaem (2021) 2(3):503–7. doi: 10.1002/jha2.249 PubMed DOI PMC
Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with b-cell non-Hodgkin lymphoma. Blood Adv (2021) 5:3053–61. doi: 10.1182/bloodadvances.2021005094 PubMed DOI PMC
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. . Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med (2015) 373:2425–37. doi: 10.1056/NEJMoa1509388 PubMed DOI PMC
Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. . Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med (2019) 381:432–43. doi: 10.1056/NEJMoa1817073 PubMed DOI PMC
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. . Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (2020) 395:1278–91. doi: 10.1016/S0140-6736(20)30262-2 PubMed DOI PMC
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink A-M, Robrecht S, et al. . Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol (2020) 21:1188–200. doi: 10.1016/S1470-2045(20)30443-5 PubMed DOI
Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, et al. . Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol (2018) 36:2395–404. doi: 10.1200/JCO.2017.76.8960 PubMed DOI
Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, et al. . Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol (2020) 95:362–71. doi: 10.1002/ajh.25711 PubMed DOI
Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. . DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol (2019) 37:912–22. doi: 10.1200/JCO.18.00915 PubMed DOI
Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, et al. . Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica (2017) 102:e156–9. doi: 10.3324/haematol.2016.151738 PubMed DOI PMC
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. . Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med (2018) 379:934–47. doi: 10.1056/NEJMoa1805104 PubMed DOI PMC
Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, et al. . Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood (2020) 135:735–42. doi: 10.1182/blood.2019003127 PubMed DOI
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. . PD-1 blockade with nivolumab in relapsed or refractory hodgkin’s lymphoma. N Engl J Med (2015) 372:311–9. doi: 10.1056/NEJMoa1411087 PubMed DOI PMC
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. . Polatuzumab vedotin in relapsed or refractory diffuse Large b-cell lymphoma. J Clin Oncol (2020) 38:155–65. doi: 10.1200/JCO.19.00172 PubMed DOI PMC
Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, Boghdadly ZE, et al. . Incidence of opportunistic infections during ibrutinib treatment for b-cell malignancies. Leukemia (2019) 33:2527–30. doi: 10.1038/s41375-019-0481-1 PubMed DOI PMC
Zinzani PL, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F, et al. . Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leuk Res (2019) 81:88–94. doi: 10.1016/j.leukres.2019.04.016 PubMed DOI
Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA. Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Rev (2018) 32:499–507. doi: 10.1016/j.blre.2018.04.007 PubMed DOI
Stefania Infante M, Fernández-Cruz A, Núñez L, Carpio C, Jiménez-Ubieto A, López-Jiménez J, et al. . Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. Cancer Med (2021) 10(21):7629–40. doi: 10.1002/cam4.4293 PubMed DOI PMC
Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect (2018) 24 Suppl 2:S83–94. doi: 10.1016/j.cmi.2018.03.022 PubMed DOI
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. . Brentuximab vedotin with chemotherapy for stage III or IV hodgkin’s lymphoma. N Engl J Med (2018) 378:331–44. doi: 10.1056/NEJMoa1708984 PubMed DOI PMC
Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. . Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood (2022) 139:678–85. doi: 10.1182/blood.2021014085 PubMed DOI PMC
Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, et al. . Antibody responses after first and second covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J (2021) 11:136. doi: 10.1038/s41408-021-00528-x PubMed DOI PMC
Shen Y, Freeman JA, Holland J, Solterbeck A, Naidu K, Soosapilla A, et al. . COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal b-lymphocytosis; humoural and cellular immunity. Br J Haematol (2021) 197(1):41–51. doi: 10.1111/bjh.18014 PubMed DOI
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. . Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood (2020) 136:1134–43. doi: 10.1182/blood.2020006965 PubMed DOI PMC
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. . COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus. Leukemia (2020) 34:2354–63. doi: 10.1038/s41375-020-0959-x PubMed DOI PMC
Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. Protective role of bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Br J Haematol (2020) 190:e73–6. doi: 10.1111/bjh.16863 PubMed DOI PMC
Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. . The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood (2020) 135:1912–5. doi: 10.1182/blood.2020006288 PubMed DOI PMC
Coutre SE, Barnett C, Osiyemi O, Hoda D, Ramgopal M, Fort AC, et al. . Ibrutinib for hospitalized adults with severe COVID-19 infection: Results of the randomized, double-blind, placebo-controlled iNSPIRE study. Open Forum Infect Dis (2022) 9(5):ofac104. doi: 10.1093/ofid/ofac104 PubMed DOI PMC
Salmanton-García J, Busca A, Cornely OA, Corradini P, Hoenigl M, Klimko N, et al. . EPICOVIDEHA: A ready to use platform for epidemiological studies in hematological patients with COVID-19. Hemasphere (2021) 5:e612. doi: 10.1097/HS9.0000000000000612 PubMed DOI PMC
Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. . COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol (2021) 14:168. doi: 10.1186/s13045-021-01177-0 PubMed DOI PMC
Langerbeins P, Eichhorst B. Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic. Acta Haematol (2021) 144:508–18. doi: 10.1159/000514071 PubMed DOI PMC
Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, et al. . COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood (2021) 138:1768–73. doi: 10.1182/blood.2021011841 PubMed DOI PMC
Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, et al. . COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and campus CLL study. Leukemia (2021) 35:3444–54. doi: 10.1038/s41375-021-01450-8 PubMed DOI PMC
Infante M-S, González-Gascón Y Marín I, Muñoz-Novas C, Churruca J, Foncillas M-Á, Landete E, et al. . COVID-19 in patients with hematological malignancies: A retrospective case series. Int J Lab Hematol (2020) 42:e256–9. doi: 10.1111/ijlh.13301 PubMed DOI PMC
Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, et al. . COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant (2020) 55(11):2180–4. doi: 10.1038/s41409-020-0931-4 PubMed DOI PMC
Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, et al. . Survival study of hospitalized patients with concurrent covid-19 and haematological malignancies. Br J Haematol 190(1):e16–e20. doi: 10.1111/bjh.16801 PubMed DOI PMC
Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, et al. . Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving b-cell-directed therapies. Blood (2021) 138:811–4. doi: 10.1182/blood.2021012443 PubMed DOI PMC
Passamonti F, Romano A, Salvini M, Merli F, Porta MGD, Bruna R, et al. . COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol (2021) 195:371–7. doi: 10.1111/bjh.17704 PubMed DOI PMC
Jacobs CF, Eldering E, Kater AP. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv (2021) 5:913–25. doi: 10.1182/bloodadvances.2020003768 PubMed DOI PMC
Rezaei M, Barati S, Babamahmoodi A, Dastan F, Marjani M. The possible role of bruton tyrosine kinase inhibitors in the treatment of COVID-19: A review. Curr Ther Res Clin Exp (2022) 96:100658. doi: 10.1016/j.curtheres.2021.100658 PubMed DOI PMC
The RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with covid-19. N Engl J Med (2021) 384:693–704. doi: 10.1056/NEJMoa2021436 PubMed DOI PMC
Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Delivery Rev (2021) 169:100–17. doi: 10.1016/j.addr.2020.12.004 PubMed DOI PMC
Zhang J, Zhang H, Sun L. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? MAbs (2022) 14:2031483. doi: 10.1080/19420862.2022.2031483 PubMed DOI PMC
Gaborit B, Vanhove B, Vibet M-A, Le Thuaut A, Lacombe K, Dubee V, et al. . Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial. Trials (2021) 22:199. doi: 10.1186/s13063-021-05132-9 PubMed DOI PMC
O’Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan K-C, Sarkar N, et al. . Subcutaneous REGEN-COV antibody combination to prevent covid-19. N Engl J Med (2021) 385:1184–95. doi: 10.1056/NEJMoa2109682 PubMed DOI PMC
